A practical reference on MC1R: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-07-26. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
| Property | Value | Notes |
|---|---|---|
| Solid-state storage | -20 degrees Celsius or lower | Desiccated and protected from light |
| Solution stability | Short and method-dependent | Confirm by stability testing |
| Purity assessment | Reversed-phase HPLC | Reported as area percent |
| Identity confirmation | LC-MS or comparable method | Mass match against expected value |
| Common synonyms | MT-II; melanotan II | Informal and catalogue names |
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
In late January, several CDC websites, pages, and datasets related to HIV and STI prevention, and LGBT and youth health became unavailable for viewing. In mid-February, around 1,300 CDC employees were laid off. In April, it was reported that among the reductions were the elimination of the Freedom of Information Act team, the Division of Violence Prevention, labs involved in testing for antibiotic resistance, and the team responsible for recalls of hazardous infant products. Additional cuts affected the technology branch of the Center for Forecasting and Outbreak Analytics, which was established during the COVID-19 pandemic. On June 25, 2025, Kennedy announced that the U.S. was stopping its donations to the Gavi vaccine alliance, until Gavi can better demonstrate vaccine safety. The United States had been providing approximately 13 percent of Gavi's budget. On August 5, 2025, Secretary Kennedy announced that he was stopping 22 vaccine projects using mRNA technology, including Covid, RSV, and bird flu. A critic of this funding halt pointed out that mRNA vaccines have the potential for faster roll-out. On December 5, 2025, it was no longer systematically recommended for newborns of mothers having never gotten Hepatitis B to get vaccinated against this infection. The memos sparked indignation among most health experts. On February 24, 2026, more than a dozen U.S.
==== Thiolated chitosan ==== Thiolated chitosan is produced by attaching thiol groups to the amino groups of chitosan using a thiol-containing coupling agent. The primary site for this modification is the amino group at the 2nd position of chitosan's glucosamine units. During this process, thioglycolic acid and cysteine mediate the reaction, forming an amide bond between the thiol group and chitosan. At a pH below 5, thiol activity is reduced, which limits disulfide bond formation. The modified chitosan exhibits improved adhesive properties and stability due to the covalent attachment of the thiol groups. Lower pH reduces oxidation, enhancing its adhesion properties. Additionally, thiolated chitosan can interact with cell membrane receptors, improving membrane permeability and showing potential for applications in bacterial adhesion prevention, for example for coating stainless steel.
Dehydrogenase enzymes transfer electrons from the substrate to an electron carrier; what carrier is used depends on the reaction taking place. Common electron acceptors used by this subclass are NAD+, FAD, and NADP+. Electron carriers are reduced in this process and considered oxidizers of the substrate. Electron carriers are coenzymes that are often referred to as "redox cofactors."
WOMAC scale, taking into account pain, stiffness and functional limitation. Kellgren-Lawrence grading scale for osteoarthritis of the knee. It uses only projectional radiography features. Tönnis classification for osteoarthritis of the hip joint, also using only projectional radiography features.
== Composition == The basic composition of a sausage roll is sheets of puff pastry formed into tubes around sausage meat and glazed with egg or milk before being baked. They can be served either hot or cold. In the 19th century, they were made using shortcrust pastry instead of puff pastry. A vegetarian or vegan approximation of a sausage roll can be made in the same manner, using a meat substitute.
Sources: en.wikipedia.org
The GHRH neurons are located in the arcuate nucleus of the hypothalamus, whereas the somatostatin cells involved in growth hormone regulation are in the periventricular nucleus. These two neuronal systems project axons to the median eminence, where they release their peptides into portal blood vessels for transport to the anterior pituitary. Growth hormone is secreted in pulses, which arise from alternating episodes of GHRH release and somatostatin release, which may reflect neuronal interactions between the GHRH and somatostatin cells, and negative feedback from growth hormone.
=== Nitrile oxides === Nitrile oxides have the chemical formula RCNO. Their general structure is R−C≡N+−O−. The R stands for any group (typically organyl, e.g., acetonitrile oxide CH3−C≡N+−O−, hydrogen in the case of fulminic acid H−C≡N+−O−, or halogen (e.g., chloroformonitrile oxide Cl−C≡N+−O−). Nitrile oxides are quite different from nitriles and do not arise from direct oxidation of the latter. Instead, they can be synthesised by nitroalkane dehydration, oxime dehydrogenation, or halooxime elimination in base. They are highly reactive in 1,3-dipolar cycloadditions, such as to isoxazoles, and undergo type I dyotropic rearrangement to isocyanates. The heavier nitrile sulfides are extremely reactive and rare, but temporarily form during the thermolysis of oxathiazolones. They react similarly to nitrile oxides.
Fusion: In this method the ingredients are melted together in descending order of their melting points and stirred to ensure homogeneity. Trituration: In this finely subdivided insoluble medicaments are evenly distributed by grinding with a small amount of the base followed by dilution with gradually increasing amounts of the base.
=== Individualization Phase === Students may complete courses in Individualization Phase, often referred to as the "Indy" Phase, at any of the University of North Carolina School of Medicine campuses or sites. In this phase, the final year of their medical education, students take a variety of elective courses designed to tailor their education toward the specialty they plan to pursue. The phase also includes support for students’ transition into residency.
=== Development discontinued === AV-608 (CGP-60829; NK-608; NKP-608C; NKP608) – neurokinin NK1 receptor antagonist Cycloserine (D-cycloserine; TIK-101; TIK101) — NMDA receptor partial agonist Tradipitant (LY-686017; VLY-686) – neurokinin NK1 receptor antagonist Verucerfont (GSK-561679; NBI-77860) – corticotropin-releasing hormone receptor 1 (CRF1) antagonist
Sources: en.wikipedia.org
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.
There is no single harmonised standard governing these products, and manufacturing conditions differ. Impurities may include truncated sequences, oxidation products, residual solvents, and counter-ions. Independent testing is often the only way to characterise a given lot.
Reported studies have looked at pigmentation, photoprotection, and metabolic or appetite-related endpoints in small experimental settings. Much of the evidence base is early-stage and limited in size. Questions about long-term effects and clinical relevance remain open.
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.